23andMe+
Total Healthtrademark
23 chromosome pairs. 55 blood biomarkers. 200x more answers. Total Health, the sum total of living your healthiest life.
Longevity: a new take on growing older.
Total Health is a longevity platform built with exome sequencing, blood biomarker analysis, and expert clinician oversight. Equipping you with the tools to age with health, productivity, and grace.
Analyzes genetics and blood for:
- Heart Health
- Brain & Nerve Health
- Cancer
- Kidney Health
- Metabolic Health
- Heart Health
- Brain & Nerve Health
- Cancer
- Kidney Health
- Metabolic Health
- Pharmacogenetics
- Liver Health
- Thyroid Health
- Blood & Immune Health
- Eye & Ear Health
- Pharmacogenetics
- Liver Health
- Thyroid Health
- Blood & Immune Health
- Eye & Ear Health
- Digestive Health
- Skin & Hair
- Lung Health
- Reproductive Health
- Digestive Health
- Skin & Hair
- Lung Health
- Reproductive Health
“Longevity isn’t about living more years. It’s about living more healthy years. And the key to doing that is within us.”
Be the architect of your health.
With exome sequencing, biannual blood analysis, and 1:1 clinician guidance, Total Health gives you the tools to build longevity and resilience in an evolving world.
Looks closer, 200x closer.
Exome Sequencing.Looks closer, 200x closer.
Exome sequencing is next level genetic screening that analyzes a portion of your total DNA, detecting 200x more disease-causing variants.‡ Total Health offers clinician-ordered sequencing and clinical interpretations of 100+ high impact genes associated with 55+ health conditions that, if detected early, may have effective preventive measures and clinical interventions.
Includes conditions that increase your risk for arrhythmia, heart attacks, and aneurysms.
Image Description: A sample result for Hereditary Cardiovascular Disease report; "No variants detected (of 44 genes tested).
Includes conditions that increase your risk for breast, ovarian, and colorectal cancer.
Image Description: A sample result for Hereditary Cancer report; "No variants detected (of 33 genes tested).
Includes conditions like Parkinson's and Alzheimer's Disease.
Image Description: A sample result for Hereditary Neurological Disease report; "A variant was detected in the APOE gene."
Hereditary Cardiovascular Disease
Includes conditions that increase your risk for arrhythmia, heart attacks, and aneurysms.
Biological Age
Change the
way you age.
Biological Age refers to how your body is aging, and is determined by analyzing biomarkers that reflect the condition of major body systems and organs. Checked biannually so you can track it and take steps to potentially slow down or even reverse course.
Blood Testing.Don’t guess, test.
With ~70% of clinical decisions relying on lab data1, Total Health tests more frequently and looks at more things. Specifically, 55+ key blood biomarkers are analyzed biannually to provide a more comprehensive picture of overall health.
Thyroid disorders can have a big impact on your health, but are often undiagnosed. TSH is used to identify hypothyroidism (too little thyroid hormone) or hyperthyroidism (too much).
Image Description: A sample result for Thyroid-stimulating hormone (TSH) report; "Your TSH levels are in the normal range."
Rarely tested, Lp(a) is the stickiest of the “bad” cholesterols and most likely to cause blockages in the arteries, increasing risk for cardiovascular disease.
Image Description: A sample result for Lipoprotein(a) (Lp(a)) report; "Your Lp(a) levels are in the optimal range."
In addition to other cholesterol testing, ApoB is being recognized as a key part of providing a more accurate and complete picture of a person’s overall risk for cardiovascular disease.
Image Description: A sample result for Apolipoprotein B (ApoB) report; "Your ApoB levels are in the moderate range."
HbA1c can help in diagnosing and monitoring prediabetes and diabetes. Most people are unaware they have prediabetes due to lack of symptoms so testing is the only way to uncover it.
Image Description: A sample result for Hemoglobin A1c (HbA1c) report; "Your HbA1c levels are in the abnormal range."
Thyroid-stimulating hormone (TSH)
Thyroid disorders can have a big impact on your health, but are often undiagnosed. TSH is used to identify hypothyroidism (too little thyroid hormone) or hyperthyroidism (too much).
Clinician Oversight.Your expert-planned action plan.
All of this sophisticated health data is only helpful if you know what to do with it. So you’ll work with an expert clinician trained in genetics-informed preventive care and health action plans. You can reach them directly via unlimited messaging, as well as an in-depth consultation tailored to your results.
Unlimited Messaging
Have ongoing conversations with clinicians about your reports, your progress or questions about your health journey.
Your path to longevity starts now.
Exome sequencing paired with enhanced blood testing, guided by expert clinicians.
- Identify disease risks with exome sequencing.Δ
- Biannual blood testing with advanced cardiometabolic biomarkers.
- Personalized health plan administered by specially trained clinicians, with unlimited messaging follow up.
- Monitor how your body is aging with Biological Age.
- Includes 23andMe+ Premium. Important test info.*
- FSA/HSA eligible⬥
- Not available to residents of HI, NJ, NY, RI and US territories.
Year
Limit 4. Offer ends Dec 9
Not available to residents of HI, NJ, NY, RI and US territories.
Things you might be wondering:
To be eligible for 23andMeplus Total Health, you must be 18 years or older and live in the US — excluding HI, NJ, NY, RI and US territories (due to state and regional restrictions). You must not have received a blood transfusion in the last 30 days or a bone marrow transplant.
Because there are multiple steps involved with 23andMeplus Total Health, your reports will arrive over a period of time after you complete certain steps. The estimated timeline is as follows:
- You’ll receive 190+ genotyping reports 4-6 weeks after registering your kit, spitting and shipping your sample.
- You’ll receive your exome sequencing reports 7-12 weeks after you receive your genotyping reports.
- For each of the two blood tests, you’ll receive your analysis of 55+ biomarkers 3-5 business days after completing your blood draw.
- You’ll have unlimited messaging with clinicians after receiving your PGS results and the opportunity to schedule your virtual consultation once exome results are returned.
All saliva samples are processed in Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited labs.
Clinical services are provided by healthcare providers which includes board-certified physicians and nurse practitioners. All clinicians have unique knowledge and training in genetics-informed care.
Genotyping examines DNA variants at certain pre-identified positions in the genome. The specific variants we look at provide coverage of common known variations across the entire genome. Many variants can be accurately and efficiently examined at once using genotyping chips, also known as microarrays. This is the technology used to power the 190+ genotyping reports that you will receive.
Sequencing is an advanced type of genetic testing which involves determining the exact sequence of a certain length of DNA - a short piece, the whole genome, or parts of the genome such as the exome. It can be used to examine known variants, as well as identify variants that are unknown, providing you with a more complete picture of your genetic predispositions for certain health conditions. Exome sequencing looks at approximately40 times more DNA bases than microarray genotyping chips.
Exome sequencing is a specialized genetic sequencing technique that focuses on decoding the exome of an individual's genome. The exome represents the protein-coding regions of genes, which make up only about 1-2% of the entire genome but contain the majority of genetic variants associated with disease risk. By selectively sequencing these regions, exome sequencing provides valuable insights into an individual's genetic makeup, identifying variations that may be linked to specific genetic disorders or conditions. This technique is particularly useful for diagnosing rare genetic diseases and conducting research into the genetic basis of various medical conditions.
The 100+ genes included in the 23andMeplus Total Health Exome Sequencing reports were carefully selected to provide high-impact genetic risk information for 55+ conditions. These include all of the genes considered “medically actionable” by the American College of Medical Genetics and Genomics (ACMG) along with other genes that can provide both clinical and personal benefit. Overall, the genes selected can inform you about conditions that are often underdiagnosed. But, if detected early, there are many effective preventive measures and clinical interventions. See a full list of the genes and conditions .
*The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of 44 variants in the BRCA1 and BRCA2 genes. The report describes if a person's genetic result is associated with an increased risk of developing breast cancer and ovarian cancer and may be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers. The variants included in this report do not represent the majority of the BRCA1/BRCA2 variants in people of most ethnicities. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. This report is for over-the-counter use by adults over the age of 18, and provides genetic information to inform discussions with a healthcare professional. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/. 23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Our SLCO1B1 Pharmacogenetics report provides certain information about variants associated with the processing of some therapeutics and provides interpretive drug information regarding the potential effect of simvastatin therapy. Our DPYD Pharmacogenetics report does not describe the association between detected variants and any specific therapeutic. Results for DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetic reports, visit 23andme.com/test-info/pharmacogenetics/
double daggerOur genotyping product detects 250 health-related variants in our Carrier Status and Genetic Health Risk reports. The Exome Sequencing reports detect 50,000+ hereditary disease-causing variants.
1 Enhancing the Clinical Value of Medical Laboratory Testing Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759162/
Source: National Library of Medicine
triangleExome Sequencing and blood testing services are available to eligible customers upon completion of the intake questionnaire that must be reviewed, approved and ordered by a third-party clinician. Exome Sequencing is analyzed by a CLIA- and CAP-accredited laboratory. Blood testing is completed by Quest Diagnostics. All telehealth services are provided in accordance with the Telehealth Terms and Consent to Telehealth.
diamondCheck with your FSA/HSA administrator or your tax professional for confirmation on the specific requirements for individual eligibility and reimbursement, including usage, procedures and qualifications